Toray, Japan Tobacco, Torii Pharmaceutical Agree to Co-Develop and Market New Antipruritus Drug in Hemodialysis Patients
Toray Industries, Inc. (Toray), Japan Tobacco Inc. (JT) and Torii Pharmaceutical Co., Ltd. (Torii) announced that the companies have reached an agreement to jointly develop and market TRK-820, a novel selective kappa opioid receptor agonist discovered by Toray's Pharmaceutical Research Laboratory, for treating uremic pruritus in hemodialysis patients in Japan.
Hemodialysis-related uremic pruritus is a condition that causes systemic and severe itching, without inflammation, on the skin and its cause has not yet been clearly elucidated. Hemodialysis patients with uremic pruritus suffer lack of sleep due to severe itching, which not only deteriorates their quality of life (QOL) but also is one of the causes of worsening of systemic condition. It is known that this type of itching is not relieved by conventional antipruritic drugs such as antihistamine agents, and the development of effective medicines has long been awaited.
TRK-820 is a compound that aims to treat uremic pruritus in patients on hemodialysis. This compound is a selective kappa opioid receptor agonist and is expected to be effective with a novel mechanism in treating itching that is resistant to existing treatments such as antihistamine agents.
The drug has entered the final phase of its clinical trials before application in Japan and further development would be jointly carried out by Toray and the JT group, with marketing to be handled by Torii.
Umicore and Solvay announced that they have sold their respective 50% stakes in joint venture SolviCoreto Japanese chemical company Toray. Since its inception in 2006, SolviCore has built up a strong portfolio of clients for its membrane electrode assemblies used in fuel cells and proton ex ... more
Toray Industries, Inc. announced that the company made a decision to expand production capacity of its PAN-based carbon fiber TORAYCA composite material simultaneously at its three manufacturing bases in Japan, the U.S. and France. The move is aimed at responding to the full-scale expansion ... more
Toray BASF PBT Resin Sdn. Bhd., a 50-50 joint venture between BASF Aktiengesellschaft, Germany, and Toray Industries Inc., Japan, has successfully started commercial production on schedule at its newly built world-scale polybutylene terephthalate (PBT) plant at BASF's Verbund site in Kuanta ... more